After 4 weeks, the sh-LINC01296 group displayed significantly reduced xenograft growth rate and size, along with remarkable up-regulation of KLF2 protein, indicating that LINC01296, as an oncogene, contributes to ESCC progression by regulating KLF2 protein expression, thereby offering potential opportunities for ESCC treatment [58]. The gene discussed is KLF2; the disease is esophageal squamous cell carcinoma.